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Abkürzungsverzeichnis 
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1. Einführung 
Heart failure (HF) is one of the most important pathologies cardiologists are 
treating all around the globe with a prevalence of about 0.4 -2 % (1). Furthermore, 
the probability of developing HF increases with age, reaching a prevalence of 8.4 % 
in people over 75 years old (2).  
According to the latest ESC guideline, heart failure can be divided according 
to the LV ejection fraction (EF) in 3 classes: HF with reduced EF (< 40 %), HF with 
mid-range EF (40 - 49 %) and HF with preserved EF (≥ 50 %) (3). Apart from 
echocardiographic assessment, symptoms and signs as well as values of natriuretic 
peptides are used to diagnose heart failure. 
Heart failure with reduced EF will be the focus of our interest as left 
ventricular assist device (LVAD) is mainly indicated in these patients. Various 
cardiac diseases, which affect the myocardium, develop heart failure usually in the 
advanced stages of progression. The most prevalent etiologies are ischemic and 
dilated cardiomyopathy. Etiology plays an important role in assessing prognosis and 
guiding further treatment. 
LVAD is indicated in acute as well as chronic HF. In the acute setting, i.e. in 
refractory cardiogenic shock, short-term use of assist devices may be warranted. 
Patient age, comorbidities and neurological status must be taken into account 
before implantation of permanent devices. The role of the assist device in this case 
is temporary, so called “bridge to decision”, allowing stabilization of the patient until 
decision about eventual heart transplant or implantation of durable assist device is 
made (4). In the chronic heart failure setting, for patients with end stage heart 
failure, LVAD implantation is growing in importance.  
LVAD concept developed from the cardiopulmonary bypass machines used 
in heart surgery (5). The heart is temporally excluded from the circulation system by 
means of the cardiopulmonary bypass machine, also called heart-lung machine 
(HLM). The HLM takes over the function of the heart by providing the pumping force 
in the circulatory system, as well as the function of the lungs, delivering oxygen and 
removing carbon dioxide from the blood (6). The same principle is used on intensive 
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care for patients with cardiac or pulmonary failure with the extracorporeal membrane 
oxygenation. Through the spectacular technological advances of the last decades, 
the concept of a similar, portable device was developed, the LVAD, taking care of 
the heart function in patients with advanced heart failure. Starting out with huge 
devices, the spectacular miniaturization process of the last decades allowed present 
LVADs to fit in a laptop bag.  
First generation devices where pulsatile, trying to imitate the cyclic heart 
contraction. Second generation devices, with axial pumps i.e. HeartMate II 
(Thoratec, Pleasanton, CA, USA) and third generation devices with centrifugal 
pumps, i.e. HVAD (HeartWare Inc., Framingham, MA, USA) produced laminar flow 
(Figure 1). Apart from the better quality of life as the noise level and size were 
significantly reduced, these LVADs proved to be less prone to infections, thrombus 
formation and device malfunction, translating in improved complication free survival 
and longer durability compared to first generation LVADs (7). 
 
Figure 1. Evolution of LVAD 
 
Left: First generation LVAD: pulsatile pump (HeartMate I, Thoratec). Middle: 
Second generation LVAD: continuous flow axial pump (HeartMate II, Thoratec). 
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Right: Third generation LVAD: continuous flow centrifugal pump (HVAD, HeartWare) 
(8).  
 
The LVAD is comprised of 3 main parts: an inflow cannula, which absorbs 
blood from the apex of the left ventricle, the rotor which provides the pumping force 
of the system, moving the blood through the circuit in a continuous laminar flow, and 
the outflow cannula, which connects the pump with the ascending aorta. The LVAD 
is powered by two external batteries that are combined with a controller and 
connected to a cable, so called driveline. The driveline is tunneled from the 
intrapericardial pump to the level of the upper abdomen, where it is externalized at 
skin level (Figure 2). 
 
Figure 2. The LVAD and its components (9) 
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In contrast to the full support provided by HLM, the LVAD pumps blood 
parallel with the heart’s own activity, so it assists the LV function instead of 
completely replacing it. Consequently, the stroke volume is provided by the 
remaining native right ventricle activity and the LVAD in different proportions for 
each patient. 
 
According to the European Society of Cardiology (ESC) HF guideline, the 
treatment algorithm of chronic heart failure comprises, apart from lifestyle changes, 
the medical treatment with angiotensin-converting enzyme inhibitors in all patients 
with the addition of beta blockers and mineralocorticoid receptor antagonists in 
symptomatic patients. Diuretics are given to treat symptoms of congestion. 
If the patients remain symptomatic under optimal medical therapy and the left 
ventricular EF (LVEF) does not increase over 35 %, the next step is to consider 
cardiac resynchronization therapy in suitable patients with QRS duration over 130 
ms (3). 
The Interagency Registry for Mechanically Assisted Circulatory Support 
(INTERMACS) has issued a classification of patients with advanced HF, utilizing 
seven clinical profiles, in the attempt to ease the decision of the cardiologist to use 
medical or device therapy in these patients (10). The INTERMACS registry was 
started in 2005, and comprises longitudinal data of all patients implanted with FDA-
approved assist device in North-America. It has generated indications and a good 
overview of complications and evolution of patients treated with LVAD. 
The 7 profiles comprise patients with symptomatic HF, with New York Heart 
Association (NYHA) class III or IV, and are divided upon hemodynamic stability, use 
of inotropes, fluid retention, renal dysfunction and symptoms, starting with 
INTERMACS level 1: cardiogenic shock, and ending with level 7: patient with NYHA 
class III and stable fluid balance. The current ESC HF guideline encourages LVAD 
implantation in patients with INTERMACS level 2 - 5, and discussion about it for 
INTERMACS level 6 and 7 patients. In case of cardiogenic shock, temporary 
hemodynamic support is warranted. 
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The initial indication for LVAD, the so called ‘bridge to transplant‘ was thought 
as a more durable hemodynamic support for selected patients, which are suitable 
for heart transplantation (HTX) (11). LVAD was shown to efficiently unload the LV, 
causing significant drop in wedge pressure. This effect lead to a reversibility of fixed 
pulmonary hypertension after several months so that these patients become 
suitable for HTX (12). Thus the concept of ‘bridge to candidacy’ was issued as a 
new LVAD indication. 
In recent years the use of LVAD for patients facing a long waiting time on the 
HTX list increased. Furthermore it was made available for patients which are 
unsuitable for HTX, as lifelong therapy: ‘destination therapy‘.  
The current HF guidelines recommendation for LVAD implantation is the 
presence of severely symptomatic HF with more than one of the following features: 
LVEF < 25 % or peakVO2 < 12 mL/kg/min, ≥ 3 hospitalizations for HF in the last 12 
months without an evident precipitating factor, need of intra-venous inotropes, 
increasing end-organ involvement (kidney, liver) as a consequence to reduced 
perfusion, lack of right ventricular failure and severe tricuspid regurgitation (3). 
Data from the INTERMACS registry certify a mortality benefit for patients with a 1-
year survival of 80 % and a 2-year survival of 70 % on LVAD therapy. In patients 
younger than 70 years old, without significant comorbidities as diabetes, renal 
impairment and not in cardiogenic shock at the implantation time point, 2-year 
survival can be as high as 85 % (13, 14). 
An analysis of the INTERMACS showed that irrespective of age, more than 70 % of 
patients on destination therapy recorded a significant improvement in quality of life 
(15). 
In recent years, the concept of ‘bridge to recovery’ has emerged, as some 
patients may recover under LVAD unloading. A recent study shows that a forced 
treatment for recovery can increase the rate of patients with successful LVAD 
explanation from 1.2 % to 11.2 % (16). 
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Functional mitral valve regurgitation (MR) is a common finding in heart failure 
patients (17). As the left ventricle dilates and the papillary muscle are displaced, 
secondary tethering of the valve leaflets occurs. 
Heart failure prevalence increases with age, and so does the prevalence of 
MR in the ageing population, affecting almost 10% of individuals above the age of 
75 years in US (18). 
The current ESC guideline on valvular disease emphasizes that there is no 
optimal management decision for secondary MR. If the systolic function is severely 
impaired (EF < 30 %), and there is no option for revascularization, the decision 
between surgery, percutaneous edge-to-edge repair, LVAD and heart transplant 
should be discussed in the heart team and individualized for each patient (19).  
Surgery of the mitral valve did not show survival benefit or superiority over 
optimal medical therapy in these patients (20). Furthermore, the Euro Heart Survey 
on valve disease revealed that in a group of 396 patients with severe symptomatic 
MR, surgery was denied in 49 % of patients. The vast majority of symptomatic 
elderly patients are not referred for surgical treatment with common reasons being 
excessive surgical risk, refuse for an open procedure, or even a lack of perceived 
survival benefit (21). 
For the MitraClip device, used in the percutaneous edge-to-edge repair, there 
was no benefit in mortality reduction until the recently published COAPT trial (22). 
Still the need for further investigation is warranted. Another MitraClip trial, published 
shortly before the COAPT trial, did not show any survival benefit of MitraClip over 
optimal medical treatment (23), leaving the cardiologist with a difficult choice as 
results diverge in the two recent studies.  
Considering LVAD in this situation is appropriate, as the pathophysiology of 
secondary MR is traced back to LV dilatation and geometry changes. Indeed LVAD 
decreases LV diameter, as it unloads the LV (24). Furthermore, numerous studies 
have shown that secondary MR improves after LVAD implantation (25, 26). 
The international society for heart and lung transplantation (ISHLT) guideline 
on assist devices does not recommend routine mitral valve intervention at the time 
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of LVAD implantation in patients with severe MR (27). Still, prospective studies are 
not available to guide clinical decisions, and study results can be controversial. 
It can be argued that adding mitral valve replacement to the LVAD operation 
increases the risk for right heart failure due to longer time on cardiopulmonary 
bypass, cardioplegia and increased operation time. A recent study showed that a 
cardio-pulmonary bypass time of > 100 min doubled the risk of right heart failure 
after surgery (28). An intervention on the valve may also cause complications 
associated with the operation technique, like circumflex artery occlusion, additional 
artificial material and the possibility of left atrial bleeding. The valve intervention also 
renders sternotomy mandatory, while simple LVAD implantation may be performed 
with minimally invasive techniques. 
Although INTERMACS analysis did not show increased survival after 
concomitant valve intervention and LVAD implantation, it has shown some 
advantages like better quality of life and lower rates of hospital admissions for these 
patients (29). Furthermore it has been shown that patients who undergo mitral valve 
replacement or repair experience a more substantial decrease in pulmonary 
vascular resistance than those who receive LVAD implantation alone (30). This may 
render some of the patients as candidates to heart transplant. Also, if recovery is 
expected, there is less concern about recurrent mitral insufficiency after LVAD 
explantation, but there are no studies researching this possibility.  
A multicentric study by Stulak et al. (31) comparing outcomes in patients with 
preoperative moderate to severe MR with those with mild MR pleaded in favor of no 
valve intervention. In contrast, a recent monocentric comparison study of Tanaka et 
al. (32) showed that the preoperative moderate to severe MR group with 
‘spontaneous’ correction after LVAD implantation still had worse outcomes at 1-year 
follow-up (i.e. survival and freedom of MR) when compared with the group with 
concomitant ‘surgical’ correction of the MR, but no difference in hospital admissions 
was noted, and clinical status was not assessed. 
This study aims to evaluate reversibility of severe MR and observe outcomes 
in patients with severe MR after LVAD implantation. We analyzed for the first time 
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echocardiographic follow-up with observations on clinical status, complications and 
survival over a prolonged follow-up period. 
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Functional mitral valve regurgitation (MR) is a common finding in heart failure 
patients (33). The pathophysiology can be traced back to the left ventricular 
dilatation and secondary tethering of the valve leaflets. Therefore, it seems logical 
that LVADs should improve MR by unloading the left ventricle (LV). Indeed, the 
international society for heart and lung transplantation (ISHLT) guideline on assist 
devices does not recommend routine mitral valve intervention at the time of LVAD 
implantation in patients with severe MR (27). Still, prospective studies are not 
available to guide clinical decisions, and study results can be controversial.  
This study aims to evaluate reversibility of severe MR and observe outcomes 
after LVAD implantation. We analyzed for the first time echocardiographic follow-up 
with observations on clinical status, complications and survival over a prolonged 
follow-up period. 
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We selected patients with good echographic window before and after LVAD 
implantation, which did not undergo additional valve surgery at the time point of 
LVAD implantation. Patients were divided in 2 groups depending on preoperative 
MR grade: Group A with severe MR (n=65), and group B with less than severe MR 
(n=63, 28 with moderate MR and 35 with mild MR). We analyzed retrospectively 
echocardiographs pre-LVAD, immediately after implantation, and in follow-up at 1, 
2, 3 and 4 - 5 years intervals, assessing MR grade, tricuspid regurgitation (TR), right 
ventricle (RV) and LV function and dimension as well as estimated pulmonary 
arterial pressure. Complications like right heart failure (defined as the need for 
extracorporeal membrane oxygenation / RVAD implantation or high urgency listing 
because of right heart failure), hospitalization due to suction events, LVAD 
thrombosis, ventricular tachycardia, ischemic stroke, bleeding events and death 
throughout follow-up were also registered. At the end of follow-up [mean of 501 (283 
– 848) days post-LVAD], we registered clinical status [i.e. New York Heart 
Association (NYHA) class]. The six-minute walking test data from 61 patients were 
also available.  
The echocardiographic follow-up data were analysed using statistical 
methods that are appropriate for the analysis of longitudinal data: for MR and TR 
severity, linear generalized estimating equations models were used and the 
remaining parameters were analysed using linear mixed models. To compare 
survival between groups, we used the Kaplan–Meier curves with the log-rank 
statistic. Analyses were performed using the SPSS software (IBM-SPSS Statistics, 
Version 20, IBM Corp.). The study was conducted in accordance with the 
Declaration of Helsinki and was approved by the local research ethics committee. 
The majority of the devices used were the HeartWare Ventricular Assist 
Device (HVAD). There were significantly more patients with non-ischemic 
cardiomyopathy in the severe MR group. 
The evolution over 5 time points − pre-LVAD, immediately after and at 1-, 2- 
and 3-year follow-up − was modelled after 4 parameters: left ventricular end-
diastolic diameter (LVDD), right ventricular end-diastolic diameter (RVDD), tricuspid 
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annular plane systolic excursion (TAPSE) and RV-right atrium (RA) pressure 
gradient. 
We observed greater LV end-diastolic diameters in the severe MR group, 
suggesting a more advanced stage of remodeling of the left heart, leading to 
annular dilatation and consecutive loss of coaptation of the valve leaflets. Despite a 
more advanced state of heart failure, this LV remodeling seems to be reversible in a 
large majority of LVAD patients. 
In our study population, we observed that LVDD decreased immediately after 
LVAD implantation in both groups to a similar degree and that the LVDD remained 
higher in the severe MR group during follow-up. The significant decrease in LVDD, 
MR severity and subsequent RV-RA gradient occurred predominantly within the 
time interval from implantation to the first echocardiographic follow-up. This effect 
was maintained at 1-year and until the 3-year follow-up, but without further 
significant change as observed within the first postoperative period. The device 
specific pump speed was similar between groups. 
These observations demonstrate the ability of the LVAD to unload the LV 
irrespective of the initial LV dimension or MR severity. The unloading of the LV 
improves the mitral insufficiency in the severe MR group and provides the same 
outcomes when compared with the non-severe MR group. This also suggests that 
MR reversal is a good marker of efficient LV unloading. 
The pattern of MR reversal demonstrated in our patient cohort suggests that 
the presence of persistent severe MR detected at the early post-LVAD 
echocardiographic study should trigger research on additional therapy strategies, 
knowing that the degree of MR will not improve on its own and could increase the 
likelihood of adverse outcomes of this subgroup of patients. 
In our study population, there was no difference between groups in terms of 
late right heart failure. This may suggest that severe MR is not necessarily 
associated with advanced RV dysfunction due to increased afterload in the long-
term follow-up but rather a reversible mechanism with a good chance of regression 
22 
 
 
 
 
 
after LVAD implantation. As noted above, there were no differences in pump speed 
and LVDD reduction between groups suggesting that there is no additional preload 
for the RV after LVAD implantation in patients with preoperative severe MR. 
The majority of studies favor tricuspid valve repair because it was not 
associated with significant increase in operative risk. Because of our patient 
selection, we cannot comment on the early RV failure incidence in patients with 
severe TR, but we did notice a definite improvement in TR at the first 
echocardiography, which was maintained throughout the follow-up.  We also 
observed that Group A developed significantly more severe TR before LVAD 
implantation. This difference disappeared at the last follow-up. This may suggest 
that the 2 pathologies were linked as they improved synergistically after LVAD 
implantation. Although patients with severe MR and TR may be considered to be in 
a more advanced phase of the disease, our findings suggest that LVADs have a 
good therapeutic potential in these patients. 
The overall survival of patients in our cohort seems to be better when 
compared with results from interagency registry for mechanically assisted circulatory 
support (INTERMACS) reports (69 % vs. 59 % at 3 years) (34) because we selected 
patients with available pre- and post-LVAD echocardiography and thus have 
excluded those who died in the immediate postoperative period. 
Although in our study there was no statistically significant difference in intermediate 
survival between patients with severe and less than severe MR before LVAD 
implantation [1- and 3-year survival (87.7 % vs. 88.4 % and 71.8 % vs. 66.6 %) for 
Groups A and B, respectively, a recent multicentre study showed even improved 
survival in patients with significant MR (31). 
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5. Anlagen 
5.1. Statistical analysis of echocardiographic parameters in follow-up 
The echocardiographic follow-up data were analyzed using statistical methods that 
are appropriate for the analysis of longitudinal data: for MR and TR severity, linear 
GEE models were used; the remaining parameters were analyzed using linear 
mixed models. For a detailed presentation of the statistical models used, see 
supplementary material. 
For the linear mixed models, correlations between the repeated measures were 
accounted by using an appropriate variance-covariance matrix in the model 
(unstructured, in case of non-convergence, exchangeable).  Two types of analysis 
were used.  For the first analysis, the baseline values were included as repeated 
measures: the model included MR severity, time (as categorical) and their 
interaction as fixed effects.  When the interaction was found to be non-significant, it 
was dropped from the model.  The effect of MR was assessed using an overall F-
test.  Similarly, the overall effect of time was assessed using an F-test.  In addition, 
for both groups, the changes from baseline were assessed using a Wald test.  A 
stepwise Bonferroni correction was used to account for multiple testing.  For the 
second analysis, only the post-baseline measurements were included as the 
repeated outcome measurements and the baseline value was included as a 
covariate.  The model further included time, MR and their interaction as fixed 
factors. As above, the interaction was dropped from the model when found to be 
non-significant.  The effect of time and group were assessed using an F-test. For 
the LVDD, RVDD, TAPSE and RV-RA pressure gradient we had few data for the 4-
5 years follow-up, so this time point was excluded from the analysis. 
MR and TR severity evolution in time was analyzed using generalized estimating 
equations (GEE) models, with identity link and normal residual distribution. Primarily 
a model including all time points was used. The GEE model included an identity 
working correlation matrix; the sandwich-estimators were used to obtain correct 
standard and robust standard errors. Similar to the linear mixed models described 
above, the data were analyzed in two ways: including the baseline value as a 
repeated measure of the outcome; and including the baseline value as a covariate. 
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The above models were used to estimate differences between groups and time 
points and their associated 2-sided 95% confidence intervals. 
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5.2. Statistical Models Used 
 LVDD (mm) RVDD(mm)  TAPSE(mm) ΔP RV-RA 
(mmHg)  
Model A 
Difference in overall 
profiles over time 
(Interaction)$ 
p=0.84 p=0.28 p=0.11 p=0.32 
Model B 
Estimated difference 
between groups 
4.6  
(95% CI 1.1; 
8.1) 
p=0.010 
2.6 
(95% CI 0.3; 
5.0) 
p=0.028 
0.6  
(95% CI -0.3; 
1.5) 
p=0.20 
4.9  
(95% CI 1.2; 
8.7) 
p=0.010 
Overall effect of time p<0.001 p=0.31 p<0.001 p<0.001 
Change from baseline 
at timepoint 1# 
-5.2 
(95% CI -6.8; 
-3.5) 
p<0.001 
1.9 
(95% CI 0.1; 
3.6) 
p=0.17 
-2.3  
(95% CI -3.0; 
-1.7) 
p<0.001 
-13.2  
(95% CI -
17.0; -9.3) 
p<0.001 
Model C 
Difference in overall 
profiles over time 
(interaction), when 
adjusted for baseline@ 
p=0.75 p=0.10 p=0.080 p=0.28 
Model D 
Estimated difference 
between groups, 
adjusted for baseline 
0.8  
(95% CI -1.9; 
3.6) 
p=0.57 
2.3  
(95% CI -
0.2; 4.8) 
p=0.067 
-0.1  
(95% CI -0.9; 
0.7) 
p=0.83 
2.0  
(95% CI -
2.9; 6.8) 
p=0.42 
Overall effect of time p=0.89 p=0.52 p=0.41 p=0.39 
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Model A is a linear mixed model of all measurements (including baseline value) 
using a model that includes MR severity, time (as categorical) and their interaction.  
$ A test for the interaction assesses whether the shape of the profiles over time 
differs between the two groups.  A significant interaction indicates that the profiles 
differ and that the difference between the two groups varies over time. 
Model B is Model A with the interaction dropped from the model, i.e. the two profiles 
are the same over time and the difference between the two groups is the same at all 
time points. # All time points were compared versus baseline and a stepwise 
Bonferroni correction was applied to the p-values, not to the confidence intervals. 
Model C is a linear mixed model of all post-baseline measurements that includes 
the baseline value, MR severity, time (categorical) and the interaction between MR 
severity and time. @ A test for the interaction assesses whether the shape of the 
profiles during follow-up differ between the two groups.  A significant interaction 
indicates that the profiles differ and that the difference between the two groups 
varies over time. 
Model D is Model C with the interaction dropped from the model, i.e. after baseline 
and adjusted for baseline, the two profiles are the same over time. 
LVDD, left ventricular enddiastolic diameter; RVDD, right ventricular enddiastolic 
diameter in 4ch (four chamber) view and SAX (short axis parasternal); TAPSE, 
tricuspid annular plane systolic excursion; ΔP RV-RA right ventricle to right atrium 
pressure gradient; CI confidence interval 
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